| pubmed-article:20458031 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0024301 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0032952 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0042679 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0879399 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0768182 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:20458031 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:20458031 | pubmed:issue | 18 | lld:pubmed |
| pubmed-article:20458031 | pubmed:dateCreated | 2010-6-18 | lld:pubmed |
| pubmed-article:20458031 | pubmed:abstractText | The efficacy and safety of cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade follicular lymphoma. | lld:pubmed |
| pubmed-article:20458031 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20458031 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20458031 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20458031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20458031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20458031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20458031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20458031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20458031 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20458031 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:20458031 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:20458031 | pubmed:author | pubmed-author:LeonardJohn... | lld:pubmed |
| pubmed-article:20458031 | pubmed:author | pubmed-author:LinkBrian KBK | lld:pubmed |
| pubmed-article:20458031 | pubmed:author | pubmed-author:MartinPeterP | lld:pubmed |
| pubmed-article:20458031 | pubmed:author | pubmed-author:KaminskiMark... | lld:pubmed |
| pubmed-article:20458031 | pubmed:author | pubmed-author:ColemanMorton... | lld:pubmed |
| pubmed-article:20458031 | pubmed:author | pubmed-author:GoldsmithStan... | lld:pubmed |
| pubmed-article:20458031 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20458031 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:20458031 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:20458031 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20458031 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20458031 | pubmed:pagination | 3035-41 | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:meshHeading | pubmed-meshheading:20458031... | lld:pubmed |
| pubmed-article:20458031 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20458031 | pubmed:articleTitle | Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. | lld:pubmed |
| pubmed-article:20458031 | pubmed:affiliation | University of Iowa Hospitals and Clinics, Iowa City, IA, USA. | lld:pubmed |
| pubmed-article:20458031 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20458031 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20458031 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:20458031 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
